Abstract: The invention concerns powder thermosetting coating compositions comprising (a) an amorphous polyester containing carboxyl groups, rich in isophthalic acid and neopentylglycol, optionally branched with a polycarboxylic acid or a polyol containing at least three functional groups; (b) a semicrystalline polyester containing carboxyl groups prepared from one or several saturated aliphatic dicarboxylic acids with linear chain, and from a saturated aliphatic diol with linear or cyclic chain optionally branched with a polycarboxylic acid or with a polyol containing at least three functional groups, and having a melting point (Tm) of at least 40° C. and an acid value of 5 to 50 mg of KOH/g, and (c) a cross-linking agent. Said compositions are useful for preparing powder paints and varnishes providing excellent quality coatings whereof the brilliance, measured at an angle of 60°, according to the ASTM D 523 standard is always less than 50%, that is half-gloss or matt coatings.

Abstract: The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferably asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.

Abstract: Thermosetting powder compositions comprising as binder a mixture of polyesters containing carboxyl groups and of a crosslinking agent having functional groups capable of reacting with the carboxyl groups.

Abstract: Phosphorus-comprising polyol, oligomer derived from this phosphorus-comprising polyol, polymer derived from this oligomer, processes for their preparation and uses of these. The present invention relates to a phosphorus-comprising polyol. The invention also relates to an oligomer derived from this phosphorus-comprising polyol and to the composition comprising this oligomer. The invention also relates to a polymer derived from this oligomer. The invention also relates to processes for the preparation of this phosphorus-comprising polyol, of this oligomer, of this polymer and of this composition. The invention also relates to the uses of this phosphorus-comprising polyol, of this oligomer, of this polymer and of this composition. The composition can be cross-linked by irradiation and exhibits flame-retardant properties.

Abstract: The invention relates to compositions comprising at least one polymer and at least one plasticizer, in which compositions the polymer is semi-crystalline and exhibits a processing temperature equal to or greater than 220° C., preferably 250° C., and the plasticizer is an aromatic benzenesulphonamide represented by the general formula (I) in which R1 represents a hydrogen atom, a C1-C4 alkyl group or a C1-C4 alkoxy group, X represents a linear or branched C2-C10 alkylene group, or a cycloaliphatic group, or an aromatic group, Y represents one of the groups OH or R2 representing a C1-C4 alkyl group or an aromatic group, these groups optionally themselves being substituted by an OH or C1-C4 alkyl group.

Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.

Abstract: Disclosed is a process for determining the presence and/or amount of antibiotics containing &bgr;-lactam ring present in a biological fluid. The process complexes the antibiotic in the biological fluid with a known amount of recognition agent, and then places the mixture of the biological fluid and recognition agent in contact with an antibiotic on a support. A determination is made of the amount of the antibiotic present in the biological fluid. Also disclosed is a kit for use in the disclosed process.

Abstract: A pharmaceutical composition comprising a therapeutically effective amount of a mixture consisting essentially of (i) pseudoephedrine, an individual optical isomer or a pharmaceutically acceptable salt thereof, and (ii) at least one compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivatives, an individual optical isomer or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to compositions comprising at least one polymer and at least one plasticizer, in which compositions the polymer is semi-crystalline and exhibits a processing temperature equal to or greater than 220° C., preferably 250° C.

Abstract: A method is described for preparing a fluid pharmaceutical composition which allows the controlled release of at least one active substance. The method involves mixing a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to 72% by weight of pharmaceutically acceptable solvent, and from 4 to 52 % by weight of fatty acid. The composition has a property of gelling instantaneously in the presence of an aqueous phase.

Abstract: A pharmaceutical composition comprising a therapeutically effective amount of a mixture consisting essentially of (i) pseudoephedrine, an individual optical isomer or a pharmaceutically acceptable salt thereof, and (ii) at least one compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivatives, an individual optical isomer or a pharmaceutically acceptable salt thereof.

Abstract: A fluid pharmaceutical composition is described which allows the controlled release of at least one active substance. The composition comprises a therapeutically effective amount of at least one active substance, from 3 to 55% by weight of phospholipid, from 16 to 72% by weight of pharmaceutically acceptable solvent, and from 4 to 52% by weight of fatty acid. The composition has a property of gelling instantaneously in the presence of an aqueous phase.

Abstract: The invention concerns a polyester bearing tertiary carboxyl groups, characterised in that it consists of: (a) 8.1 to 35 moles of an aliphatic or cycloaliphatic of a polyol; (b) 9.1 to 36 moles of an aliphatic, cycloaliphatic or aromatic polycarboxylic acid; (c) 1.6 to 2.8 moles of an aliphatic, cycloaliphatic or aromatic compound comprising a tertiary carboxyl group and either a primary or secondary carboxyl group, or a primary or secondary hydroxyl group. Said polyester is prepared in several steps, the first steps consisting in the preparation of a polyester by condensation between (a) an aliphatic or cycloaliphatic polyol, and (b) an aliphatic, cycloaliphatic or aromatic polycarboxylic acid, the final step consisting in condensing said polyester with (c) an aliphatic, cycloaliphatic or aromatic compound comprising a tertiary carboxyl group and either a primary or secondary carboxyl group, or a primary or secondary hydroxyl group.

Abstract: The invention concerns pharmaceutical compositions for oral administration, comprising an active substance belonging to the family of substituted benzhydrylpiperazines and at least a cyclodextrin.

Abstract: The present invention provides 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted, 4-alkylidenyl peperidines compounds. The compounds of the invention are dual acting molecules having both leukotriene inhibition properties as well as antihistaminergic properties. The compounds of the invention are useful for treating conditions in which there is likely to be a histamine and/or leukotriene component. These conditions include preferable asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, thrombotic disease and otitis media. Also provided are methods of treating asthma and rhinitis by administering an effective asthma and rhinitis-relieving amount of the compounds to a subject in need thereof.

Abstract: A multi-layer film including: (a) a substrate layer of a thermoplastic polymer film having opposed first and second surfaces; and (b) a heat sealable layer associated with the first surface of the substrate and including (i) a first acrylic polymer and (ii) a second polymer which is a copolymer including residues derived from one or more olefinically unsaturated monomers and residues derived from one or more olefinically unsaturated monomers which include one or more functional groups. The first polymer (i) has a glass transition temperature in the range of from 40 to 120° C. and a weight average molecular weight in the range of from 20,000 to 60,000, the second polymer (ii) is a copolymer of a C1-C4 olefinically unsaturated hydrocarbon and an olefinically unsaturated carboxylic acid, and the heat-sealable layer includes from 5 to 60% by weight of the first acrylic polymer and from 40 to 95% by weight of the second polymer.

Abstract: Levorotatory and dextrorotatory enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl]piperazine of the formula their preparation and use for the preparation of substantially optically pure enantiomers of 1-[(4-chlorophenyl)phenylmethyl]piperazine, which are themselves valuable intermediate products for the preparation of optically active therapeutic compounds having a very high degree of optical purity.

Abstract: The present invention relates to a method for preventing the onset of asthma which comprises administering to a patient a therapeutically effective amount of cetirizine, an individual optical isomer thereof or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.

Abstract: The present invention relates to a novel method for the production of tetramethylthiuram disulfide, in which dimethylammonium dimethyldithiocarbamate is oxidized in aqueous solution with oxygen, in the presence of carbon disulfide and a lignosulfonate.